Tobi employs high-throughput phage display screens to tackle a critical unmet need in Pancreatic Cancer– the lack of diagnostic biomarkers. By panning phage libraries containing billions of synthetic antibodies on patient-derived organoids, Tobi aims to discover pancreatic cancer-specific antibodies that can reliably detect the presence of early disease.